Loading filters...
50 results(scroll for more)
GeneralAll Stages2026
Effect of Case Discussion with Expert Centers on Treatment Outcome of Intrahepatic Cholangiocarcinoma.
Zwaan TC et al. Ann Surg Oncol. 2026
GeneralAdvanced/Metastatic2026
Low-dose chemotherapy remodels hepatic immune landscape and potentiates anti-tumor response to immune checkpoint blockade in cholangiocarcinoma.
Zhixing L et al. Hepatology. 2026
GeneralAll Stages2026
Extracellular Vesicle-Mediated O-GlcNAcase Transfer Drives Neuronal Necroptosis to Facilitate Gallbladder Cancer Perineural Invasion.
Zhao J et al. Cancer Res. 2026
GeneralResectable2026
Long-term Outcomes in Gallbladder Cancer Patients Treated with Curative-Intent Resection: Adjuvant Chemotherapy Versus Observation in a Multicenter Propensity Score-Matched Study.
Yu LY et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Impact of Additional Resection on Outcomes in Patients with Positive Proximal Margin of Perihilar Cholangiocarcinoma: A Systematic Review and Network Meta-analysis.
Yang DL et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Reappraisal of the Clinical Utility of Hi-Cut Pancreaticoduodenectomy for Widespread Distal Cholangiocarcinoma: A Less Invasive Alternative to Hepatopancreatoduodenectomy.
Umino R et al. Ann Surg Oncol. 2026
GeneralAdvanced/Metastatic2026
Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.
Ishikawa S et al. Eur J Cancer. 2026
GeneralAll Stages2026
Eligibility for Liver Transplantation in Patients with Intrahepatic Cholangiocarcinoma.
Schleimer LE et al. Ann Surg Oncol. 2026
GeneralResectable2026
Retroperitoneal-First Laparoscopic Approach (Retlap) for Bile Duct Resection in Pancreaticobiliary Maljunction (PBM): A Novel and Reasonable Approach to Intrapancreatic Bile Duct.
Karasuyama T et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
PARG inhibition halts cholangiocarcinoma progression via the Hippo pathway and enhances response to chemotherapy and immunotherapy.
Yu M et al. J Hepatol. 2026
GeneralAdvanced/Metastatic2026
Outcomes of First Versus Second-Line Hepatic Artery Infusion Chemotherapy in Unresectable Intrahepatic Cholangiocarcinoma.
Nasar N et al. Ann Surg Oncol. 2026
IDH1/2 mutantAll Stages2026
MAPK Pathway Mutations Emerge in Mutant IDH1 Inhibitor-Resistant Cholangiocarcinoma and Attenuate the IFN Response.
Wan J et al. Clin Cancer Res. 2026
GeneralAdvanced/Metastatic2026
Excessive Dissection of Nonmetastatic Tumor-Draining Lymph Nodes Impairs Immunotherapy Efficacy in Recurrent Biliary Tract Cancer.
Long Y et al. Clin Cancer Res. 2026
GeneralAll Stages2026
Association Between Metabolic Syndrome and Long-Term Prognosis in Patients with Perihilar Cholangiocarcinoma Treated with Curative-Intent Resection: A Multicenter Study.
Liu ZP et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Tumor Burden Modifies the Prognostic Impact of Adequate Lymph Node Dissection in Patients Undergoing Curative-Intent Resection for Intrahepatic Cholangiocarcinoma.
Kawashima J et al. Ann Surg Oncol. 2026
GeneralAdvanced/Metastatic2026
Outcomes After Resection for Multiple Intrahepatic Cholangiocarcinoma-A National Population-Based Study.
Jansson H et al. Ann Surg Oncol. 2026
FGFR alteredAdvanced/Metastatic2026
Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.
Abou-Alfa GK et al. ESMO Open. 2026
ImmunotherapyAll Stages2026
Nivolumab and ipilimumab combination treatment in patients with advanced intrahepatic cholangiocarcinoma and gallbladder cancer: Results from the phase II MoST-CIRCUIT trial.
Nagrial A et al. Clin Cancer Res. 2026
GeneralAll Stages2026
Intracholecystic Papillary Neoplasms (ICPNs): Systematic Review and Meta-analysis of Epidemiological, Diagnostic, Immunohistochemical, and Clinical Features.
Rompianesi G et al. Ann Surg Oncol. 2026
GeneralAll Stages2026
Preoperative Chemotherapy with Gemcitabine and Cisplatin for Biliary Tract Cancer Does Not Affect Liver Regeneration Induced by Portal Vein Embolization.
Hyakutake Y et al. Ann Surg Oncol. 2026
ImmunotherapyAdvanced/Metastatic2026
Robotic Left Hepatectomy with Hilar Dissection and Portal Lymphadenectomy Following Preoperative Gemcitabine, Cisplatin, and Pembrolizumab for Intrahepatic Cholangiocarcinoma.
Gonzalez JFS et al. Ann Surg Oncol. 2026
GeneralResectable2026
Neoadjuvant GOLP in Resectable High-Risk Intrahepatic Cholangiocarcinoma.
Shi GM et al. N Engl J Med. 2026
FGFR alteredAdvanced/Metastatic2026
Pemigatinib for Unresectable or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor-2 Rearrangement: Results From the Phase 3 FIGHT-302 Trial.
Bekaii-Saab TS et al. J Clin Oncol. 2026
FGFR alteredAll Stages2026
Recurrent Resistance Mutations to Lirafugratinib Inform Treatment Sequencing in FGFR2-Driven Tumors.
Facchinetti F et al. Clin Cancer Res. 2026
GeneralResectable2026
Real-world outcomes of adjuvant therapy after curative-intent resection for biliary tract cancer.
Dong Y et al. Eur J Cancer. 2026
GeneralResectable2026
Neoadjuvant Therapy as a Selection Strategy for Curative Resection in High-Risk Intrahepatic Cholangiocarcinoma.
Dong Y et al. Ann Surg Oncol. 2026
GeneralResectable2026
Liver resection with and without vascular resection versus transplantation for de novo perihilar cholangiocarcinoma.
Dong Y et al. Hepatology. 2026
ImmunotherapyAll Stages2025
Laparoscopic Extended Segmentectomy 8 with Right Hepatic Vein Resection After Conversion Therapy for Advanced Intrahepatic Cholangiocarcinoma.
Tan W et al. Ann Surg Oncol. 2025
ImmunotherapyAll Stages2025
A Multimodality Treatment Strategy for an Intrahepatic Cholangiocarcinoma and Complex Liver Resection with Vascular Reconstruction-A Video Vignette.
Shah N et al. Ann Surg Oncol. 2025
ImmunotherapyAdvanced/Metastatic2025
Genomic pathway alterations and their prognostic impact in biliary tract cancer: Insights from a multinational cohort treated with cisplatin, gemcitabine, and durvalumab.
Pirrone C et al. Eur J Cancer. 2025
GeneralAdvanced/Metastatic2025
Bintrafusp alfa and chemotherapy as first-line treatment in biliary tract cancer: A randomized phase 2/3 trial.
Oh DY et al. Hepatology. 2025
GeneralAdvanced/Metastatic2025
Molecular profile and clinical impact of MDM2 amplification in patients with advanced biliary tract cancer.
Yoon H et al. ESMO Open. 2025
GeneralAdvanced/Metastatic2025
Association of KRAS variants with survival and therapeutic outcomes in biliary tract cancers.
Iida K et al. ESMO Open. 2025
ImmunotherapyAdvanced/Metastatic2025
Molecular targeted maintenance therapy versus standard of care in advanced biliary cancer: an international, randomised, controlled, open-label, phase III umbrella trial (SAFIR-ABC10-Precision Medicine).
Malka D et al. ESMO Open. 2025
ImmunotherapyAll Stages2025
Durvalumab plus chemotherapy in advanced biliary tract cancer: 3-year overall survival update from the phase III TOPAZ-1 study.
Oh DY et al. J Hepatol. 2025
GeneralAdvanced/Metastatic2025
A phase III randomized study of first-line NUC-1031/cisplatin vs. gemcitabine/cisplatin in advanced biliary tract cancer.
Knox JJ et al. J Hepatol. 2025
ImmunotherapyAdvanced/Metastatic2025
Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study.
Yoo C et al. J Hepatol. 2025
GeneralAdvanced/Metastatic2025
The efficacy of second-line chemotherapy for advanced biliary tract cancer: A systematic review and network meta-analysis.
Hwang I et al. J Hepatobiliary Pancreat Sci. 2025
ImmunotherapyAll Stages2025
Bile acids activate cancer-associated fibroblasts and induce an immunosuppressive microenvironment in cholangiocarcinoma.
Huang F et al. Cancer Cell. 2025
FGFR alteredAdvanced/Metastatic2025
Genomic correlates of response and resistance to the irreversible FGFR1-4 inhibitor futibatinib based on biopsy and circulating tumor DNA profiling.
Goyal L et al. Ann Oncol. 2025
GeneralAll Stages2025
Real-World Single-Center Experience with Neoadjuvant Gemcitabine, Cisplatin, and Durvalumab in Borderline Resectable Cholangiocarcinoma.
Dong Y et al. Ann Surg Oncol. 2025
GeneralAdvanced/Metastatic2025
New platinum derivatives selectively cause double-strand DNA breaks and death in naïve and cisplatin-resistant cholangiocarcinomas.
Olaizola I et al. J Hepatol. 2025
GeneralAdvanced/Metastatic2025
Association of candidate surrogate endpoints with overall survival in advanced biliary tract cancer.
Castet F et al. J Hepatol. 2025
HER2 amplifiedAll Stages2025
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.
Wilding B et al. Cancer Discov. 2025
GeneralAdvanced/Metastatic2024
Real-world evidence of systemic treatment practices for biliary tract cancer in Japan: Results of a database study.
Ueno M et al. J Hepatobiliary Pancreat Sci. 2024
ImmunotherapyAdvanced/Metastatic2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
Burris HA et al. Lancet Oncol. 2024
ImmunotherapyAll Stages2024
Syngeneic murine models with distinct immune microenvironments represent subsets of human intrahepatic cholangiocarcinoma.
Tomlinson JL et al. J Hepatol. 2024
ImmunotherapyAll Stages2024
Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT).
Roth GS et al. Eur J Cancer. 2024
ImmunotherapyAdvanced/Metastatic2024
Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer: A large real-life worldwide population.
Rimini M et al. Eur J Cancer. 2024
FGFR alteredAll Stages2024
PTPN9 dephosphorylates FGFR2 pY656/657 through interaction with ACAP1 and ameliorates pemigatinib effect in cholangiocarcinoma.
Zhao L et al. Hepatology. 2024